US-based contract research organisation (CRO) Medpace has raised its European profile by acquiring Medical Consulting Dr Schlichtiger GmbH, a CRO based in Germany with particular expertise in regulatory and drug safety, for an undisclosed sum.
Founded by general manager Dr Ursula Schlichtiger in 1989, Medical Consulting provides customised regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies throughout Europe from its headquarters in Munich.
Medpace said the acquisition would supplement its strategic expertise by providing centralised European hubs for regulatory submissions and product approvals as well as drug safety management and reporting. Schlichtiger is joining the Medpace team as managing director and senior director of medical and regulatory affairs for Europe.
The integration of Medical Consulting Dr. Schlichtiger GmbH will begin immediately and should be completed by mid-2010. “The leaders at Medical Consulting will continue in their roles as our businesses integrate for the significant benefit of our clients,” Medpace added.
New headquarters
The US company has also started building new corporate headquarters in Cincinatti’s Madisonville district. The plan is that the 132,000 sq ft facility will be the first of at least two separate office buildings for Medpace on the 29-acre development.
The company “is growing rapidly and will bring its current 600 employees from Norwood [Greater Cincinatti] to the new facility, as well as add an estimated 750 new jobs by the year 2014”, Medpace noted.
